SAB Biotherapeutics (SABS) Earnings Date, Estimates & Call Transcripts $2.58 +0.62 (+31.63%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.55 -0.03 (-1.16%) As of 07/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SAB Biotherapeutics Earnings Summary SAB Biotherapeutics released Q1 2025 earnings on May 9, 2025, reporting an EPS of -$0.56, which beat the consensus estimate of -$1.00 by $0.44. With a trailing EPS of -$3.70, SAB Biotherapeutics' earnings are expected to grow next year, from ($3.69) to ($2.98) per share. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 9) -$1.00 Actual EPS (May. 9) -$0.56 Beat By $0.44 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)SABS Upcoming EarningsSAB Biotherapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Powered by Get SAB Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataSABS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SABS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. SAB Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$1.14-$1.14-$1.14Q2 20252-$1.10-$0.58-$0.84Q3 20252-$0.44-$0.43-$0.44Q4 20252-$0.42-$0.39-$0.41 SAB Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/9/2025Q1 2025-$1.00-$0.56+$0.44-$0.56$0.13M-3/28/2025Q4 2024-$1.16-$1.23 -$0.07-$1.23$0.12M$0.05M11/6/2024--$1.07-$1.12 -$0.05-$1.12$0.50M-8/8/2024--$1.13-$0.79+$0.34-$0.79-$0.26M5/20/2024Q1 2024-$0.98-$0.54+$0.44-$0.54-$0.95M11/13/2023Q3 2023-$0.10-$0.10--$0.10-$1.27M8/21/2023Q2 2023-$0.14-$0.14--$0.14-$0.09M SAB Biotherapeutics Earnings - Frequently Asked Questions When is SAB Biotherapeutics' earnings date? SAB Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on SABS's earnings history. Did SAB Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, SAB Biotherapeutics (NASDAQ:SABS) reported ($0.56) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.00) by $0.44. Learn more on analysts' earnings estimate vs. SABS's actual earnings. How much revenue does SAB Biotherapeutics generate each year? SAB Biotherapeutics (NASDAQ:SABS) has a recorded annual revenue of $1.32 million. How much profit does SAB Biotherapeutics generate each year? SAB Biotherapeutics (NASDAQ:SABS) has a recorded net income of -$34.10 million. SABS has generated -$3.70 earnings per share over the last four quarters. What is SAB Biotherapeutics' EPS forecast for next year? SAB Biotherapeutics' earnings are expected to grow from ($3.69) per share to ($2.98) per share in the next year. More Earnings Resources from MarketBeat Related Companies Fortress Biotech Earnings Curis Earnings Bolt Biotherapeutics Earnings Molecular Templates Earnings Amgen Earnings Gilead Sciences Earnings Vertex Pharmaceuticals Earnings Regeneron Pharmaceuticals Earnings Alnylam Pharmaceuticals Earnings Biogen Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs This page (NASDAQ:SABS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SABS Stock Alerts